Biological treatment of vein grafts and stents in lower-extremity arterial reconstruction.
Longevity of lower-extremity revascularization procedures has typically been limited because of restenosis of grafts, as well as stents and other percutaneous techniques. The ability to prevent or ameliorate neointimal hyperplasia and improve durability of lower-extremity arterial reconstruction is the focus of significant scientific and clinical research. The transcription factor decoy edifoligide was investigated as a potential inhibitor of neointimal hyperplasia, but the results of the pivotal clinical trial did not demonstrate significant improvement in graft reintervention, although secondary patency was improved. Similar to the coronary circulation, drug-eluting stents are a potential tool for prevention of restenosis after percutaneous arterial reconstruction. The SIROCCO study did not demonstrate improvement in superficial femoral artery stent patency with sirolimus-eluting stents. Studies are underway that are investigating paclitaxel-eluting stents for use in the superficial femoral artery. Other potential mediators of restenosis include absorbable drug-eluting stents and antibody-coated stents designed to promote endothelialization of the stent or graft surface. In addition, absorbable wraps eluting paclitaxel can be used at arterial and arteriovenous anastomoses to prevent restenosis. Clinical trials investigating these novel technologies are underway.
Morrissey
Nicholas J
NJ
Columbia University College of Physicians and Surgeons, Columbia/Weill Cornell Division of Vascular Surgery, the New York Presbyterian Hospital, New York, USA. njm2106@ columbia.edu
D001157:Arterial Occlusive Diseases / Q000473:pathology / Q000601:surgery*; D019917:Blood Vessel Prosthesis Implantation; D054855:Drug-Eluting Stents; D006083:Graft Occlusion, Vascular / Q000000981:diagnostic imaging / Q000517:prevention & control; D006801:Humans; D006965:Hyperplasia; D007866:Leg / Q000098:blood supply*; D009841:Oligonucleotides / Q000627:therapeutic use; D017239:Paclitaxel / Q000008:administration & dosage; D011859:Radiography; D017539:Tunica Intima / Q000473:pathology; D014654:Vascular Patency
D009841:Oligonucleotides; C502518:edifoligide; D017239:Paclitaxel